Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
Patent 6121319 Issued on September 19, 2000. Estimated Expiration Date: May 14, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
This invention is a method and composition for the inhibition of VCAM-1, and in particular for the treatment of cardiovascular or inflammatory disease, including atherosclerosis, that includes the administration of an effective amount of an ester of probucol.
Other References
Baron, J.L. et al., J. Clin. Invest. 93, 1700-1708 (1994)
Brown and Goldstein, Ann. Rev. Biochem. 52, 223 (1983)
Burkly, L.C. et al., Diabetes 43, 523-534 (1994)
Carew et al. Proc. Natl. Acad. Sci. U.S.A. 84:7725-7729 (1987)
Folkman, J. and Shing, Y., Biol. Chem. 10931-10934 (1992)
Heeg et al., Plasma Levels of Probucol in Man After Single and Repeated Oral Doses, La Nouvelle Presse Medicale, 9(40) (1980)
Kazuya et al. J. Lipid Res. 32; 197-204 (1991)
Koch, A.E. et al. Lab. Invest. 64, 313-322 (1991)
Miller, Ann. Rev. Med. 31,97 (1980)
Morales-Ducret, J. et al., Immunol. 149, 1421-1431 (1992)
Ohkawara, Y., et al., Am. j. Respir. Cell Mol. Biol. 12,4-12 (1995)
Oroez, C.G. et al., Immunol. Lett. 32, 7-12 (1992)
Parthasarathy, S. et al., Probucol Inhibits Oxifative Modification of Low Density Lipoprotein, J. Clin. Invest., 77 641-644 (1986)
May 14, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
